About: Novel potent pharmacological CDK inhibitors - a review of the patent literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel potent pharmacological CDK inhibitors - a review of the patent literature Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Progression of the cell cycle is controlled by various activating and inhibiting cellular factors. The subtle balance between these counteracting regulators in normal cells ensures proper cell cycle progression and facilitates cellular responses to a variety of stress stimuli. Key activators include cyclin-dependent kinases (CDKs), consequently loss or inactivation of CDK inhibitors contributes to the escape of cancer cells from cell cycle control and hyperactivation of CDKs occurs in various neurodegenerative disorders. However, these adverse effects may be compensated by pharmacological counterparts. Discussion: Inhibitors of CDKs representing various classes of compounds with diverse CDK inhibitory patterns have been developed, but inhibitors that have high selectivity, and offer highly targeted activity against both cell cycle and transcriptional CDKs are of particular interest. This review focuses on pharmacological CDK inhibitors that have entered clinical trials and some compounds Background: Progression of the cell cycle is controlled by various activating and inhibiting cellular factors. The subtle balance between these counteracting regulators in normal cells ensures proper cell cycle progression and facilitates cellular responses to a variety of stress stimuli. Key activators include cyclin-dependent kinases (CDKs), consequently loss or inactivation of CDK inhibitors contributes to the escape of cancer cells from cell cycle control and hyperactivation of CDKs occurs in various neurodegenerative disorders. However, these adverse effects may be compensated by pharmacological counterparts. Discussion: Inhibitors of CDKs representing various classes of compounds with diverse CDK inhibitory patterns have been developed, but inhibitors that have high selectivity, and offer highly targeted activity against both cell cycle and transcriptional CDKs are of particular interest. This review focuses on pharmacological CDK inhibitors that have entered clinical trials and some compounds (en)
Title	Novel potent pharmacological CDK inhibitors - a review of the patent literature Novel potent pharmacological CDK inhibitors - a review of the patent literature (en)
skos:prefLabel	Novel potent pharmacological CDK inhibitors - a review of the patent literature Novel potent pharmacological CDK inhibitors - a review of the patent literature (en)
skos:notation	RIV/61989592:15310/09:00010045!RIV10-MSM-15310___
http://linked.open...avai/riv/aktivita	P S Z
http://linked.open...avai/riv/aktivity	P(GA204/08/0511), S, Z(MSM6198959216)
http://linked.open...iv/cisloPeriodika	9
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Kryštof, Vladimír Chamrád, Ivo
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Přírodovědecká fakulta
http://linked.open...dnocenehoVysledku	330055
http://linked.open...ai/riv/idVysledku	RIV/61989592:15310/09:00010045
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	apoptosis, cell cycle, cyclin-dependent kinase; inhibitors of cyclin-dependent kinases; RNA polymerase II, transcription (en)
http://linked.open.../riv/klicoveSlovo	inhibitors of cyclin-dependent kinases transcription cyclin-dependent kinase RNA polymerase II apoptosis cell cycle
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[0EE7CFB5770E]
http://linked.open...i/riv/nazevZdroje	Future Medicinal Chemistry
http://linked.open...in/vavai/riv/obor	CE
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	3 (xsd:int)
http://linked.open...vavai/riv/projekt	Biological activity of synthetic inhibitors of cyclin-dependent kinases
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	1
http://linked.open...iv/tvurceVysledku	Kryštof, Vladimír Chamrád, Ivo Węsierska-Gądek, Jozefa
http://linked.open...n/vavai/riv/zamer	Modulation of signalling and regulatory pathways in normal and cancer cells
issn	1756-8919
number of pages	21 (xsd:int)
http://localhost/t...ganizacniJednotka	15310
is http://linked.open...avai/riv/vysledek of	Novel potent pharmacological CDK inhibitors - a review of the patent literature Novel potent pharmacological CDK inhibitors - a review of the patent literature Novel potent pharmacological CDK inhibitors - a review of the patent literature Novel potent pharmacological CDK inhibitors - a review of the patent literature

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software